@article{Shabbir_Liaqat_Muhammad Atif_2022, title={Successful Eradication of Hepatitis C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients: Eradication of HCV with Sofosbuvir in cirrhotic patients}, volume={5}, url={https://www.pakistanbmj.com/journal/index.php/pbmj/article/view/385}, DOI={10.54393/pbmj.v5i4.385}, abstractNote={<p>Hepatitis C virus (HCV) infection has long been a serious global public health concern; it is not only the main cause of end-stage liver disease, but it is also a leading source of liver cancer, but it also increases the risk of mortality from a variety of extrahepatic illnesses. <strong>Objective: </strong>The study’s main objective is to see if successfully eradicating the Hepatitis-C virus with sofosbuvir-based antiviral therapy improves cirrhotic patients’ quality of life.<strong> Methods: </strong>This cross-sectional study was conducted in Faisalabad Medical University from June 2019 to June 2020. The data was collected from 70 patients. The data was collected through a non-probability consecutive sampling technique. <strong>Results: </strong>The data were collected from 70 patients of both genders. We compared patients’ quality of life. With sofosbuvir and ribavirin, 56 patients (79%) reached Sustained Virologic Response 12 (SVR12), Sofosbuvir, daclatasvir, and ribavirin were administered to 13 patients (18%), while sofosbuvir and ledipasvir were administered to two individuals (3%).<strong>Conclusions:</strong> Infection with chronic HCV, which is made worse by cirrhosis, has a major negative influence on the patient’s physical, mental, social, and functional well-being, leading to a considerable reduction in their overall quality of life. </p>}, number={4}, journal={Pakistan BioMedical Journal}, author={Shabbir, Abdul Basit and Liaqat, Mahrukh and Muhammad Atif, Hafiz}, year={2022}, month={Apr.}, pages={141–144} }